This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lim, S. C. Articles by Veves, A. Search for Related Content PubMed PubMed Citation Articles by Lim, S. C. Articles by Veves, A.

The Effect of Hormonal Replacement Therapy on the Vascular Reactivity and Endothelial Function of Healthy Individuals and Individuals with Type 2 Diabetes¹

Joslin Diabetes Center (S.C.L., A.E.C., E.M.B., F.M.B., E.S.H.), Microcirculation Laboratory (P.S., F.W.L., A.V.), Department of Medicine (A.V.), and Division of Vascular Surgery (S.A., F.W.L.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215

Address correspondence and requests for reprints to: Aristidis Veves, M.D., Microcirculation Laboratory, Palmer 317, Beth Israel Deaconess Medical Center, West Campus, One Deaconess Road, Boston, Massachusetts 02215. E-mail: aveves{at}caregroup.harvard.edu

Estrogens protect healthy women from cardiovascular disease. However, epidemiological data suggest that women with diabetes are denied the cardioprotection associated with estrogens. Whether or not hormonal replacement therapy (HRT) confers cardiovascular benefits in postmenopausal women with diabetes is not known. The aim of this study was to examine the effects of HRT on the microvascular reactivity and endothelial function of individuals with and without diabetes. We studied the following groups of individuals: premenopausal healthy women [n = 28, age 41 ± 8 yr (mean ± SD)], premenopausal women with type 2 diabetes (n = 16, age 43 ± 6 yr); postmenopausal healthy women (n = 12, age 57 ± 4 yr), postmenopausal women with diabetes (n = 17, age 62 ± 5 yr); postmenopausal healthy women on HRT (n = 13, age 51 ± 5 yr), postmenopausal women with diabetes on HRT (n = 11, age 57 ± 7 yr). We used laser Doppler flowmetry to measure forearm cutaneous vasodilatation in response to iontophoresis of 1% acetylcholine (endothelium dependent) and 1% sodium nitroprusside (endothelium independent). The endothelium-dependent vasodilation was significantly higher in premenopausal healthy women (180 ± 67%; increase over baseline) compared to premenopausal diabetic women (87 ± 41%; P < 0.001). endothelium-dependent vasodilation was also higher in postmenopausal healthy women on HRT (143 ± 52) compared with postmenopausal diabetic women on HRT (86 ± 61), postmenopausal healthy women without HRT (104 ± 43), and postmenopausal diabetic women without HRT (74 ± 28; P < 0.001). A similar pattern of responses was observed in the endothelium-independent vasodilation (premenopausal healthy women, 126 ± 56; premenopausal diabetic women, 88 ± 26; postmenopausal healthy women on HRT, 121 ± 37; postmenopausal diabetic women on HRT, 88 ± 41; postmenopausal healthy women without HRT, 84 ± 36; and postmenopausal diabetic women without HRT, 73 ± 36; P < 0.001). Soluble intercellular adhesion molecule (sICAM) was also measured among all the women with diabetes. Premenopausal women with diabetes (248.9 ± 56 ng/ml) and postmenopausal women with diabetes on HRT (257.7 ± 49 ng/ml) had lower sICAM levels compared with the postmenopausal diabetic women without HRT (346.4 ± 149 ng/ml; P < 0.05). We conclude that menopausal status and type 2 diabetes are associated with impaired microvascular reactivity. HRT substantially improves microvascular reactivity in postmenopausal healthy women. In contrast, the effect of HRT on the microvascular reactivity of postmenopausal diabetic women is less apparent. However, the use of HRT among women with diabetes is associated with lower sICAM levels, suggesting an attenuation in endothelial activation.

This article has been cited by other articles:

				B. Litschauer, G. Schaller, and M. Wolzt Naloxone does not influence cardiovascular responses to mild mental stress in postmenopausal women Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2120 - H2125. [Abstract] [Full Text] [PDF]

				A. F. Kernohan, A. Spiers, N. Sattar, C. Hillier, S. J Cleland, M. Small, M.-A. Lumsden, J. M. Connell, and J. R Petrie Effects of low-dose continuous combined HRT on vascular function in women with type 2 diabetes Diabetes and Vascular Disease Research, October 1, 2004; 1(2): 82 - 88. [Abstract] [PDF]

				S. Y. Honisett, L. Stojanovska, K. Sudhir, B. A. Kingwell, T. Dawood, and P. A. Komesaroff Hormone Therapy Impairs Endothelial Function in Postmenopausal Women with Type 2 Diabetes Mellitus Treated with Rosiglitazone J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4615 - 4619. [Abstract] [Full Text] [PDF]

				K. K. Koh, M. H. Kang, D. K. Jin, S.-K. Lee, J. Y. Ahn, H. Y. Hwang, S. H. Yang, D. S. Kim, T. H. Ahn, and E. K. Shin Vascular effects of estrogen in type II diabetic postmenopausal women J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1409 - 1415. [Abstract] [Full Text] [PDF]

				O. Hamdy, K. Abou-Elenin, F. W. LoGerfo, E. S. Horton, and A. Veves Contribution of Nerve-Axon Reflex-Related Vasodilation to the Total Skin Vasodilation in Diabetic Patients With and Without Neuropathy Diabetes Care, February 1, 2001; 24(2): 344 - 349. [Abstract] [Full Text]

				K. N. Hogeveen, M. Talikka, and G. L. Hammond Human Sex Hormone-binding Globulin Promoter Activity Is Influenced by a (TAAAA)n Repeat Element within an Alu Sequence J. Biol. Chem., September 21, 2001; 276(39): 36383 - 36390. [Abstract] [Full Text] [PDF]